v3.26.1
Income Taxes - Schedule of deferred tax assets and liabilities (Details) - USD ($)
Dec. 31, 2025
Dec. 31, 2024
Income Taxes    
Net operating loss carry forwards $ 29,960,000 $ 28,438,000
Orphan drug and research and development credit carry forwards 10,298,000 9,617,000
Equity based compensation 44,000 227,000
Intangible and fixed assets 1,410,000 1,401,000
Capitalized research and development 3,497,000 2,482,000
Lease Liability 37,000 69,000
Other   (85,000)
Total 45,246,000 42,149,000
Valuation allowance (45,216,000) (42,087,000)
Net deferred tax assets 30,000 62,000
Right of use asset (30,000) (62,000)
Total gross deferred tax liabilities (30,000) (62,000)
Net deferred tax assets $ 0 $ 0